ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 184 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $258 | -62.3% | 23,058 | -27.9% | 0.02% | -67.6% |
| Q2 2023 | $684 | -56.1% | 31,972 | -16.9% | 0.07% | -55.8% |
| Q1 2023 | $1,557 | +202.9% | 38,493 | +248.1% | 0.15% | +140.6% |
| Q4 2022 | $514 | -99.8% | 11,057 | +76.0% | 0.06% | +106.5% |
| Q2 2021 | $276,000 | -43.8% | 6,281 | -41.4% | 0.03% | -62.2% |
| Q3 2020 | $491,000 | +137.2% | 10,715 | +159.3% | 0.08% | -28.7% |
| Q2 2020 | $207,000 | -77.4% | 4,132 | -72.1% | 0.12% | +7.5% |
| Q4 2019 | $916,000 | +219.2% | 14,829 | +210.3% | 0.11% | +174.4% |
| Q3 2019 | $287,000 | -72.0% | 4,779 | -60.7% | 0.04% | -66.1% |
| Q2 2019 | $1,026,000 | -30.3% | 12,160 | -21.0% | 0.12% | -22.8% |
| Q1 2019 | $1,471,000 | +67.5% | 15,400 | +24.2% | 0.15% | +47.5% |
| Q4 2018 | $878,000 | -32.4% | 12,400 | -18.4% | 0.10% | +40.3% |
| Q3 2018 | $1,299,000 | -54.1% | 15,200 | -37.7% | 0.07% | -48.6% |
| Q2 2018 | $2,828,000 | +503.0% | 24,400 | +320.7% | 0.14% | +460.0% |
| Q1 2018 | $469,000 | -15.0% | 5,800 | -38.3% | 0.02% | -26.5% |
| Q4 2017 | $552,000 | -40.1% | 9,400 | -52.3% | 0.03% | -46.0% |
| Q3 2017 | $922,000 | +216.8% | 19,700 | +143.2% | 0.06% | +231.6% |
| Q2 2017 | $291,000 | -88.8% | 8,100 | -89.5% | 0.02% | -87.7% |
| Q4 2016 | $2,590,000 | +19.1% | 77,309 | -5.4% | 0.16% | +32.5% |
| Q3 2016 | $2,175,000 | -28.1% | 81,740 | -40.4% | 0.12% | -29.9% |
| Q2 2016 | $3,026,000 | -18.7% | 137,240 | +8.3% | 0.17% | -29.5% |
| Q1 2016 | $3,720,000 | +40.3% | 126,675 | +57.7% | 0.24% | +82.3% |
| Q4 2015 | $2,652,000 | +31.9% | 80,322 | +44.3% | 0.13% | +31.3% |
| Q3 2015 | $2,011,000 | -15.5% | 55,652 | +5.2% | 0.10% | +8.8% |
| Q2 2015 | $2,380,000 | +25.9% | 52,910 | -14.3% | 0.09% | +21.3% |
| Q1 2015 | $1,890,000 | +416.4% | 61,709 | +757.1% | 0.08% | +188.5% |
| Q4 2014 | $366,000 | -60.1% | 7,200 | -69.0% | 0.03% | -45.8% |
| Q3 2014 | $918,000 | – | 23,200 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |